MI Visit the ASPET Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Molecular Interventions 5:163-171, (2005)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.5.3.6
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peng, X.
Right arrow Articles by Sawyer, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peng, X.
Right arrow Articles by Sawyer, D. B.
Review

The Cardiotoxicology of Anthracycline Chemotherapeutics: TRANSLATING MOLECULAR MECHANISM INTO PREVENTATIVE MEDICINE

Xuyang Peng, Billy Chen, Chee Chew Lim and Douglas B. Sawyer

Whitaker Cardiovascular Institute and Center for Molecular Stress Response, Boston University Medical Center, 650 Albany Street, Boston, MA 02118


{Sawyer_Titleart}

Anthracyclines remain a mainstay of chemotherapy in spite of their well-recognized cardiotoxicity. Recent experience with trastuzumab (Herceptin) and anthracycline therapy has prompted a detailed analysis of the function of erbB2 in the heart. These studies demonstrate a cardioprotective effect of neuregulin, the endogenous ligand for the erbB4/erbB2 heterodimeric receptor complex. Although the mechanisms of cytoprotection remain incompletely understood, these studies have triggered the question of whether physiological manipulation of cardioprotective pathways that involve erbB can be used to improve outcome in patients treated with anthracyclines. The local activation of cardioprotection by cardiovascular exercise may be such a manipulation and warrants further investigation.




This article has been cited by other articles:


Home page
 Integr Cancer TherHome page
K. Y. Wonders and B. S. Reigle
Trastuzumab and Doxorubicin-Related Cardiotoxicity and the Cardioprotective Role of Exercise
Integr Cancer Ther, March 1, 2009; 8(1): 17 - 21.
[Abstract] [PDF]

Home page
 Mol Cancer ResHome page
G. Hua, B. Zhu, F. Rosa, N. Deblon, J. Adelaide, B. Kahn-Perles, D. Birnbaum, and J. Imbert
A Negative Feedback Regulatory Loop Associates the Tyrosine Kinase Receptor ERBB2 and the Transcription Factor GATA4 in Breast Cancer Cells
Mol. Cancer Res., March 1, 2009; 7(3): 402 - 414.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. D. Venkatakrishnan, K. Dunsmore, H. Wong, S. Roy, C. K. Sen, A. Wani, J. L. Zweier, and G. Ilangovan
HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest
Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1736 - H1744.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Li, Q. Pan, W. Han, Z. Liu, L. Li, and X. Hu
Schisandrin B Prevents Doxorubicin-Induced Cardiotoxicity via Enhancing Glutathione Redox Cycling
Clin. Cancer Res., November 15, 2007; 13(22): 6753 - 6760.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. Belardinelli
Exercise Training in Chronic Heart Failure: How to Harmonize Oxidative Stress, Sympathetic Outflow, and Angiotensin II
Circulation, June 19, 2007; 115(24): 3042 - 3044.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.